ReviewThe Journal of allergy and clinical immunology2014
Progress in HIV-1 vaccine development.
Review in The Journal of allergy and clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 95 citations in OpenAlex.
- Elicitation of stem-directed antibodies in rhesus macaques by a conventional hemagglutinin immunogen.bioRxiv : the preprint server for biology · 2026Article
- CXCL13 promotes broad immune responses induced by circular RNA vaccines.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- PLGA Particles in Immunotherapy.Pharmaceutics · 2023Review
- Autoreactivity and broad neutralization of antibodies against HIV-1 are governed by distinct mutations: Implications for vaccine design strategies.Frontiers in immunology · 2022Article
- The Importance of Cellular Immune Response to HIV: Implications for Antibody Production and Vaccine Design.DNA and cell biology · 2022Review
- Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail.iScience · 2020Article
- 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.Science immunology · 2020Article
- Deconvolving mutational patterns of poliovirus outbreaks reveals its intrinsic fitness landscape.Nature communications · 2020Article
- Review
- Review
- HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis.Journal of virology · 2018Article
- Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.AIDS research and therapy · 2017Review
- Germinal center enhancement by extended antigen availability.Current opinion in immunology · 2017Review
- Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Nature communications · 2017Article
- Review
- Article
- Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model.PLoS biology · 2017Article
- Current views on the potential for development of a HIV vaccine.Expert opinion on biological therapy · 2017Review
- Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.Immunological reviews · 2017Review
- Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.Immunological reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The past 2 years have seen a number of basic and translational science advances in the quest for development of an effective HIV-1 vaccine. These advances include discovery of new envelope targets of potentially protective antibodies, demonstration that CD8(+) T cells can control HIV-1 infection, development of immunogens to overcome HIV-1 T-cell epitope diversity, identification of correlates of transmission risk in an HIV-1 efficacy trial, and mapping of the coevolution of HIV-1 founder envelope mutants in infected subjects with broad neutralizing antibodies, thereby defining broad neutralizing antibody developmental pathways. Despite these advances, a promising HIV-1 vaccine efficacy trial published in 2013 did not prevent infection, and the HIV-1 vaccine field is still years away from deployment of an effective vaccine. This review summarizes what some of the scientific advances have been, what roadblocks still remain, and what the most promising approaches are for progress in design of successful HIV-1 vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.